474
Participants
Start Date
August 31, 2011
Primary Completion Date
July 31, 2014
Study Completion Date
July 31, 2014
esomeprazole (Nexium®, AstraZeneca AB, Södertälje, Sweden)
"Each enrolled patient receives an 80 mg loading dose of intravenous esomeprazole (Nexium®, AstraZeneca AB, Södertälje, Sweden) immediately after hemostasis was achieved spontaneously or by gastroscopy. Patients then received a 3-day continuous high dose (8 mg per hour) of esomeprazole infusion. Then, patients with Rockall score \>=6 are randomized into the double oral dose group and the regular oral dose group. Patients with Rockall score \<6 are assigned to the control group.~In the double oral dose group, patients receive 40 mg oral esomeprazole twice daily for 11 days and followed by 40 mg once daily for 14 days. In the other two groups, patients receive 40 mg oral esomeprazole 40 mg once daily for 25 days."
National Cheng Kung University Hospital, Tainan City
National Science and Technology Council, Taiwan
OTHER_GOV
National Cheng-Kung University Hospital
OTHER